Riad Sherif

2 months ago | healio.com | Riad Sherif |Eamon Dreisbach |Christine Klimanskis

KOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2025, Riad Sherif, MD,CEO of Oculis, discusses data on OCS-05 for the treatment of acute optic neuritis. “The main goal of OCS-05 is to prevent retinal ganglion cells from dying and to have a neuroprotective effect,” he said.

Jan 6, 2025 | healio.com | Anthony DeFino |Christine Klimanskis |Riad Sherif

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: The phase 2 ACUITY trial evaluated OCS-05 at 2 mg/kg/day and 3 mg/kg/day. The trial met safety and efficacy endpoints.

Nov 4, 2024 | healio.com | Riad Sherif |Anthony DeFino |Christine Klimanskis

November 04, 2024 3 min watch VIDEO: Oculis highlights pipeline of eye drop treatments Add topic to email alerts Please provide your email address to receive an email when new articles are posted on Ophthalmic Business. Subscribe You've successfully added Ophthalmic Business to your alerts. You will receive an email when new content is published. Click Here to Manage Email AlertsBack to Healio We were unable to process your request. Please try again later.

Jul 5, 2024 | healio.com | Riad Sherif |Kate Young |Heather Biele

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Topline results from the phase 2b RELIEF trial demonstrate that licaminlimab has the potential to reshape the treatment paradigm of dry eye disease, offering a more precise strategy than current methods.